TREAT-NMD has developed a toolkit for patient organisations and professionals to assist setting up of registries for neuromuscular disorders (www.treat-nmd.eu/healthcare/patient-registries/toolkit). 4. Conclusions TREAT-NMD is committed to delivering innovative treatments for rare neuromuscular diseases, starting with muscular dystrophies and spinal muscular atrophy, from laboratory
development to clinical practice via the generation of a durable and sustainable network coordination centre. Although the roots of the network are within the EU 6th framework programme, the collaborations and work of the network now extends globally Inhibitors,research,lifescience,medical with members all across the world. Engagement with industry, patient groups and academia is growing with the realisation that the challenges of the Inhibitors,research,lifescience,medical new therapeutic era in NMD requires an increasing commitment to collaboration (4). More selleck chemicals information on all aspects of the network, including
how to become a member, and how to contribute to its activities can be found at www.treat-nmd.eu.
Families were included when two siblings showed a LGMD phenotype Inhibitors,research,lifescience,medical with a more than ten-fold elevation of serum creatine kinase, and the findings of muscle biopsy and mutation analysis of CAPN3 confirmed the diagnosis of LGMD2A in at least one Inhibitors,research,lifescience,medical sibling. Information on age at onset and course of the disease were collected by chart review and each patient was examined clinically by one of the authors. Muscle biopsies were analyzed by routine histology in 9/16 patients and Western blot analysis using a Calpain-3 antibody (sellckchem Novocastra) was performed in 6/16 patients. Mutation analysis was performed by direct sequencing of the 24 exons and flanking intronic sequences of
CAPN3 after PCR from genomic DNA, as previously Inhibitors,research,lifescience,medical described (3). Case study We identified 8 families with 2 affected siblings (Table (Table1).1). Of the 16 patients, 10 were female and 6 male with an age range from 9.5 to 36.8 years (mean 21.8, SD 9.6). The mean age at onset of LGMD2A, in these patients, was 9.3 years (range 4-17 years). Within siblings, the difference of age at disease onset Drug_discovery was between 1 and 11.5 years (mean 3.1 years). First symptoms were toe walking, weakness in the lower limbs, proximal weakness, and scapular winging. In 4 patients, the first recognized distinctive feature was an increased CK between 1300 and 8688 U/L (mean 4290 U/L). CK level at onset was markedly increased in all patients tested (mean 4046 U/L) and there was no difference between the sexes. Current age of the patients is between 9.5 and 36.8 years and 4 patients are no longer able to walk independently (patients 2A, 2B, 7B, 8A). Seven sib pairs have the same or similar clinical course and symptoms.